Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Slides:

Advertisements

Similar presentations

Evaluating cell lines as tumor models by comparison of genomic profiles Domcke, S. et al. Nat. Commun 4:2126.

Advertisements

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.

Fig. 3. Copy number loss as a potential resistance mechanism in an independent cohort. Copy number loss as a potential resistance mechanism in an independent.

WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.

Fig. 2. Mutational signature exposures in Taiwan HCCs and summary of AA signature mutations. Mutational signature exposures in Taiwan HCCs and summary.

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

Evolving Gene Therapy in Primary Immunodeficiency

Intravenous delivery of reovirus to primary and secondary brain tumors

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

Fig. 3 CSF1 is expressed in human melanoma.

Correlation of reovirus RNA/protein with proliferating tumor cells

Landscape of genomic alterations in 444 tumors from 429 patients with mCRPC. Landscape of genomic alterations in 444 tumors from 429 patients with mCRPC.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 7 Correlation of NHP and human ISGs.

Fig. 1. Distribution of TTNtv in healthy individuals and DCM patients, and TTN exon usage in the heart. Distribution of TTNtv in healthy individuals and.

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 3. Comparison of prediction performance.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

Fig. 5. In vivo characterization of adipogenesis by CT.

Fig. 2 Estimate of the neoantigen repertoire in human cancer.

Fig. 1. Value proposition. Value proposition.Summarized are the valuation estimates (log scale), from panel members (selected by A.W.L.) for the NCATS.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

Fig. 2 LYM attractor metagene.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Colonization in tumor models and different modes of administration

Fig. 5. Vitamin B12 supplementation in the host altered the transcriptome of P. acnes in the skin microbiota. Vitamin B12 supplementation in the host altered.

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

Fig. 3 Photon number statistics resulting from Fock state |l, S − l〉 interference. Photon number statistics resulting from Fock state |l, S − l〉 interference.

The microchip-based drug delivery device and overview of study design

Fig. 7. CIVO performance in canine lymphoma tumors demonstrates spatially restricted responses linked to drug mechanism. CIVO performance in canine lymphoma.

Fig. 1. A model to explain the pleiotropy of CEP290 disease.

Fig. 2. Mutational signature exposures in Taiwan HCCs and summary of AA signature mutations. Mutational signature exposures in Taiwan HCCs and summary.

Fig. 5 Active-state hallmarks of US28 bound to CX3CL1.

Frequent alterations identified and potential actionability.

Left ventricular ejection fraction in patients without CAD (no CAD), with established CAD without MI (CAD, no MI), and patients with CAD and previous MI.

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

Personalized genomic analyses for cancer mutation discovery and interpretation by Siân Jones, Valsamo Anagnostou, Karli Lytle, Sonya Parpart-Li, Monica.

Representative CT and PET/CT images of three patients with NSCLCs

by Wei-Yi Cheng, Tai-Hsien Ou Yang, and Dimitris Anastassiou

The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.

Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 2. Overexpression of miR cluster in the developing heart results in increased cardiomyocyte proliferation and cardiomegaly. Overexpression.

Fig. 4. Plaque-associated microglia and astrocytes and brain cytokines were altered in APP/PS1;C3 KO mice compared to APP/PS1 mice. Plaque-associated microglia.

Delineating cancer evolution with single-cell sequencing

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Fig. 4 CO2 emission changes triggered by the JJJ clean air policy.

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Fig. 1 Relevance of therapies for treating retinal degeneration and stage of disease. Relevance of therapies for treating retinal degeneration and stage.

Fig. 5. High burdens of AA signature mutations and predicted immunogenicity in Taiwan HCCs. High burdens of AA signature mutations and predicted immunogenicity.

Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.

Fig. 3. miR overexpression leads to increased cell proliferation as well as altered differentiation and metabolism in cardiomyocytes. miR

Fig. 4 The three DBT cycles involved in building syn3.0.

STK11/LKB1 mutations are a genomic determinant of poor clinical outcome with PD-1 axis blockade in PD-L1–positive nonsquamous NSCLC, regardless of KRAS.

High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.

Fig. 3. Association between peak CTL019 expansion and response.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Fig. 8 Immune correlates of protection.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Fig. 3 Postnatal assembly of the humanized gut microbiota.

Evaluating the performance of the robotic system through comparison with human trackers. Evaluating the performance of the robotic system through comparison.

Fig. 3 Genome editing of the MSTN gene.

Fig. 1. Maps of Lesotho, a landlocked country within South Africa.

Presentation transcript:

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types. Each bar represents the fraction of cases with mutations in clinically actionable genes as determined by the comparison of alterations to genes that were associated with established FDA-approved therapies (brown), previously published clinical trials (green), or current clinical trials in the same tumor type (blue). For approved therapies and previously published clinical trials, potential actionability was also considered in tumor types that were different from those where the clinical use has been described (light brown and light green, respectively). Some of the colorectal tumors analyzed were from patients with tumors known to be KRAS wild type, resulting in a lower fraction of cases with actionable changes related to FDA-approved therapies. Siân Jones et al., Sci Transl Med 2015;7:283ra53 Copyright © 2015, American Association for the Advancement of Science